The Latest in Follicular Lymphoma

FDA places partial hold on trials after secondary lymphoma

April 25, 2018

Follicular Lymphoma

Inhibitor outperforms rivals in leukemia, lymphoma

April 20, 2018

Follicular Lymphoma

PDPK1 could be novel target in MCL

April 13, 2018

FDA grants priority review of follicular lymphoma drug

April 11, 2018

Follicular Lymphoma

Tazemetostat exhibits antitumor activity in phase 1 trial

April 11, 2018

Follicular Lymphoma

Duvelisib NDA granted priority review

April 10, 2018

Follicular Lymphoma

Experimental voxtalisib shows mixed results in phase 2 study

March 22, 2018

Outpatient CAR T infusions feasible using liso-cel

March 12, 2018

Best options for treating relapsed/refractory PTCL

March 8, 2018

Follicular Lymphoma

Company withdraws application for idelalisib

March 1, 2018

Follicular Lymphoma

Basiliximab/BEAM may improve post-ASCT outcomes in PTCL

February 21, 2018

Follicular Lymphoma

Assay identifies actionable mutations in lymphoid malignancies

February 9, 2018

Follicular Lymphoma

Combo is preferentially active in T-cell lymphomas

February 7, 2018

Follicular Lymphoma

TRANSCEND NHL trial identifies window for CAR T expansion

February 6, 2018

Follicular Lymphoma

BTK inhibitor zanubrutinib active in non-Hodgkin lymphomas

January 2, 2018